- Home
- TXMD vs INAB Comparison
TXMD vs INAB Comparison
Compare TXMD & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TXMD
- INAB
- Stock Information
- Founded
- TXMD 2008
- INAB 2016
- Country
- TXMD United States
- INAB United States
- Employees
- TXMD N/A
- INAB N/A
- Industry
- TXMD Biotechnology: Pharmaceutical Preparations
- INAB Biotechnology: Pharmaceutical Preparations
- Sector
- TXMD Health Care
- INAB Health Care
- Exchange
- TXMD Nasdaq
- INAB Nasdaq
- Market Cap
- TXMD 12.3M
- INAB 10.8M
- IPO Year
- TXMD N/A
- INAB 2021
- Fundamental
- Price
- TXMD N/A
- INAB $2.35
- Analyst Decision
- TXMD
- INAB Strong Buy
- Analyst Count
- TXMD 0
- INAB 2
- Target Price
- TXMD N/A
- INAB $108.00
- AVG Volume (30 Days)
- TXMD 16.0K
- INAB 84.2K
- Earning Date
- TXMD 11-11-2025
- INAB 11-11-2025
- Dividend Yield
- TXMD N/A
- INAB N/A
- EPS Growth
- TXMD N/A
- INAB N/A
- EPS
- TXMD N/A
- INAB N/A
- Revenue
- TXMD $2,559,000.00
- INAB N/A
- Revenue This Year
- TXMD $427.09
- INAB N/A
- Revenue Next Year
- TXMD N/A
- INAB N/A
- P/E Ratio
- TXMD N/A
- INAB N/A
- Revenue Growth
- TXMD 156.93
- INAB N/A
- 52 Week Low
- TXMD $0.70
- INAB $1.91
- 52 Week High
- TXMD $2.44
- INAB $16.70
- Technical
- Relative Strength Index (RSI)
- TXMD 44.55
- INAB 64.40
- Support Level
- TXMD $0.99
- INAB $2.30
- Resistance Level
- TXMD $1.11
- INAB $2.49
- Average True Range (ATR)
- TXMD 0.03
- INAB 0.14
- MACD
- TXMD 0.00
- INAB 0.04
- Stochastic Oscillator
- TXMD 57.85
- INAB 93.88
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.